ARIKAYCE ® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --NDA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback